Maker of sample-preparation and molecular testing technologies for life-science research, applied testing and molecular diagnostics.
Maker of sample-preparation and molecular testing technologies for life-science research, applied testing and molecular diagnostics.
Places instruments in labs and earns mostly on the consumable kits used on them: each test run uses a kit, so the installed base of machines generates repeat purchases. Its QuantiFERON tuberculosis blood test is run as a kit by testing labs. It is Dutch-domiciled, with most sales in the US and Europe.
Moat: narrow (installed base, switching costs, IP / patents). Entrenched sample-prep technology embedded in customers' validated workflows across research and diagnostics.
Headquarters: Venlo, Netherlands · Founded: 1984 · Employees: 5,654
Size Qiagen (QGEN) is a United States Health Care company (Medical Specialties) with a market value of $10.2B, the 753rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $49.56 on 18 Nov 2026.
Performance Over six months the shares gained 41.2%, against +27.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +7.2%); the operating margin is 25.1% (peer median 13.7%).
Valuation It trades at 19.5× forward earnings against a peer median of 20.6× (10th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.3 points above its cost of capital (7.5% WACC).
Short interest Short interest is 3.1% of the free float (30 Oct 2026).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.12B | $2.09B | $1.98B | $1.97B | $2.14B |
| Revenue growth | — | +6% | +1% | -8% | — |
| Gross profit | $1.32B | $1.29B | $1.25B | $1.22B | $1.37B |
| EBITDA | $736M | $735M | $698M | $651M | $785M |
| Net income | $385M | $425M | $83.6M | $341M | $423M |
| Free cash flow | $436M | $453M | $506M | $310M | $586M |
| Capital expenditure | $203M | $207M | $171M | $163M | $149M |
| Total debt | $1.64B | $1.81B | $1.51B | $1.61B | $1.96B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Qiagen QGEN | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Illumina ILMN | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | QGEN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.4% | +6.1% | 7th lowest of 21 |
| 6-month return | +41.2% | +27.4% | 6th highest of 21 |
| Distance from 52-week high | -14.3% | -11.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +2.2% | +7.2% | 7th lowest of 21 |
| Operating margin | 25.1% | 13.7% | 2nd highest of 21 |
| Forward P/E | 19.5× | 20.6× | 10th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 8.6% | 10.6% | 9th least demanding of 20 |
| Growth delivered (Del g) | +2.2% | +10.0% | 4th lowest of 20 |
| Hurdle (Req g minus delivered) | +6.4 pp | +2.0 pp | 7th most demanding of 20 |
| ROIC minus cost of capital | +2.3 pp | +2.4 pp | 10th lowest of 21 |
| EV / EBITDA | 15.0× | 12.4× | 5th most expensive of 19 |
| Net debt / EBITDA | 1.1× | 0.6× | 9th most indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |